TGF-β Cancer Research Results

TGF-β, transforming growth factor-beta: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-CS TCGA
Type:
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses.
Anti-inflammatory cytokine.
In normal tissues, TGF-β plays an essential role in cell cycle regulation, immune function, and tissue remodeling.
- In early carcinogenesis, TGF-β typically acts as a tumor suppressor by inhibiting cell proliferation and inducing apoptosis.

In advanced cancers, cells frequently become resistant to the growth-inhibitory effects of TGF-β.
- TGF-β then switches roles and promotes tumor progression by stimulating epithelial-to-mesenchymal transition (EMT), cell invasion, metastasis, and immune evasion.

Non-canonical (Smad-independent) pathways, such as MAPK, PI3K/Akt, and Rho signaling, also contribute to TGF-β-mediated responses.

Elevated levels of TGF-β have been detected in many advanced-stage cancers, including breast, lung, colorectal, pancreatic, and prostate cancers.
 - The switch from a tumor-suppressive to a tumor-promoting role is often associated with increased TGF-β production and activation in the tumor microenvironment.

High TGF-β expression or signaling activity is frequently correlated with aggressive disease features, resistance to therapy, increased metastasis, and poorer overall survival in many cancer types.
NA, Not Available: Click to Expand ⟱
none (reserved)
Scientific Papers found: Click to Expand⟱
1124- ALA,    Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells
- in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, HTH-83 - in-vitro, Thyroid, CAL-62 - in-vitro, Thyroid, FTC-133 - in-vivo, NA, NA
TumCP↓, AMPK↑, mTOR↓, TumCMig↓, TumCI↓, EMT↓, E-cadherin↑, β-catenin/ZEB1↓, Vim↓, Snail↓, Twist↓, TGF-β↓, p‑SMAD2↓, TumCG↓,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, KDR/FLK-1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
1399- BBR,  Rad,    Radiotherapy Enhancing and Radioprotective Properties of Berberine: A Systematic Review
- Review, NA, NA
*ROS↓, *MDA↓, *TNF-α↓, *TGF-β↓, *IL10↑, ROS↑, DNAdam↑, mtDam↑, MMP↓, Apoptosis↑, TumCCA↑, Hif1a↓, VEGF↓, RadioS↑,
1206- Caff,    Caffeine inhibits TGFβ activation in epithelial cells, interrupts fibroblast responses to TGFβ, and reduces established fibrosis in ex vivo precision-cut lung slices
- in-vitro, NA, NA - ex-vivo, NA, NA
Fibrosis↓, TGF-β↓, α-SMA↓,
805- GAR,  Cisplatin,  PacT,    Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells
- Review, NA, NA
ERK↓, PI3K/Akt↓, Wnt/(β-catenin)↓, STAT3↓, NF-kB↓, ChemoSen↑, COX2↓, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, VEGF↓, TGF-β↓, HATs↓, E-cadherin↑, Vim↓, Zeb1↓, ZEB2↓, Let-7↑, MMP9↓, TumCCA↑, ROS↑, MMP↓, IL6↓, NOTCH1↓,
941- Gos,  Rad,    The Lactate Dehydrogenase Inhibitor Gossypol Inhibits Radiation-Induced Pulmonary Fibrosis
- in-vivo, NA, NA
lactateProd↓, other↓, TGF-β↓,
1798- NarG,    Naringenin: A potential flavonoid phytochemical for cancer therapy
- Review, NA, NA
*Inflam↓, *antiOx↓, neuroP↑, hepatoP↑, AntiCan↑, Apoptosis↑, TumCCA↑, angioG↓, ROS↝, SOD↑, TGF-β↓, Treg lymp↓, IL1β↓, *BioAv↝, ChemoSen↑, cardioP↑,
3250- PBG,    Allergic Inflammation: Effect of Propolis and Its Flavonoids
- Review, NA, NA
*SOD↑, *GPx↑, *Catalase↑, *Prx↑, *HO-1↑, *Inflam↓, *TNF-α↓, *IL1β↓, *IL4↑, *IL10↑, *TLR4↓, *LOX1↓, *COX1↓, *COX2↓, *NF-kB↓, *AP-1↓, *ROS↓, *GSH↑, *TGF-β↓, *IL8↓, *MMP9↓, *α-SMA↓, *MDA↓,
4485- Se,    Selenium stimulates the antitumour immunity: Insights to future research
- Review, NA, NA
*antiOx↑, chemoPv↑, ROS↑, Imm↑, selenoP↑, *IL2↑, *IL4↑, *TNF-α↓, *TGF-β↓, *EMT↓, Risk↓, *GPx↑, *TrxR↑,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
3405- TQ,  doxoR,    Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity and the underlying mechanism
- vitro+vivo, NA, NA
*cardioP↑, *NRF2↑, *HO-1↑, *ROS↓, *NQO1↑, *COX2↓, *NOX4↓, *GPx4↑, *FTH1↑, *p‑mTOR↓, *TGF-β↓,
1058- UA,    Ursolic acid, an antagonist for transforming growth factor (TGF)-beta1
- in-vivo, NA, NA
TGF-β↓,

Showing Research Papers: 1 to 12 of 12

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 12

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   ROS↓, 1,   ROS↑, 4,   ROS↝, 1,   selenoP↑, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   MMP↓, 3,   mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   cMyc↓, 1,   lactateProd↓, 1,   PI3K/Akt↓, 1,   SIRT1↓, 1,   SREBP1↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 3,   BAX↑, 1,   Bcl-2↓, 1,   Casp↑, 1,   Casp3↑, 1,   Casp9↑, 1,   p‑Chk2↑, 1,   Cyt‑c↑, 1,   Ferroptosis↑, 1,   oncosis↑, 1,   p27↑, 2,   survivin↓, 1,   Telomerase↓, 1,  

Transcription & Epigenetics ⓘ

HATs↓, 1,   HATs↑, 1,   other↓, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 1,  

DNA Damage & Repair ⓘ

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   DNAdam↑, 2,   HR↓, 1,   p16↑, 1,   RAD51↓, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   cycD1/CCND1↓, 1,   cycE1↓, 1,   P21↑, 1,   TumCCA↑, 5,  

Proliferation, Differentiation & Cell State ⓘ

CD44↓, 1,   cMET↓, 1,   EMT↓, 2,   ERK↓, 3,   HDAC↓, 1,   IGFBP3↑, 1,   Let-7↑, 1,   mTOR↓, 2,   NOTCH↓, 1,   NOTCH1↓, 1,   PI3K↓, 1,   STAT3↓, 2,   TumCG↓, 2,   Wnt↓, 1,   Wnt/(β-catenin)↓, 2,  

Migration ⓘ

CA↓, 1,   Ca+2↑, 1,   CDK4/6↓, 1,   E-cadherin↑, 3,   FAK↓, 1,   Fibrosis↓, 1,   ITGB1↑, 1,   miR-203↑, 1,   MMP2↓, 2,   MMP9↓, 2,   NCAM↑, 1,   PDGF↓, 1,   p‑SMAD2↓, 1,   Snail↓, 1,   TGF-β↓, 8,   TIMP2↑, 1,   Treg lymp↓, 1,   TumCI↓, 1,   TumCMig↓, 2,   TumCP↓, 1,   Twist↓, 1,   uPA↓, 1,   Vim↓, 3,   Zeb1↓, 2,   ZEB2↓, 1,   α-SMA↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   EGFR↓, 2,   Hif1a↓, 3,   KDR/FLK-1↓, 1,   NO↓, 1,   VEGF↓, 5,  

Barriers & Transport ⓘ

NHE1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IL1↓, 2,   IL1β↓, 1,   IL6↓, 2,   Imm↑, 1,   MIP2↓, 1,   NF-kB↓, 3,   PD-L1↓, 1,   PGE2↓, 2,   PSA↓, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   ChemoSen↑, 2,   Dose↝, 1,   eff↝, 1,   Half-Life↓, 1,   Half-Life↝, 1,   RadioS↑, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

AR↓, 1,   EGFR↓, 2,   IL6↓, 2,   PD-L1↓, 1,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   cardioP↑, 2,   chemoP↑, 1,   chemoPv↑, 1,   hepatoP↑, 2,   neuroP↑, 1,   Risk↓, 1,   toxicity↝, 1,   toxicity∅, 1,  
Total Targets: 128

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 2,   Catalase↑, 1,   GPx↑, 2,   GPx4↑, 1,   GSH↑, 1,   HO-1↑, 2,   MDA↓, 2,   NOX4↓, 1,   NQO1↑, 1,   NRF2↑, 1,   Prx↑, 1,   ROS↓, 3,   SOD↑, 1,   TrxR↑, 1,  

Metal & Cofactor Biology ⓘ

FTH1↑, 1,  

Core Metabolism/Glycolysis ⓘ

SIRT1↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   p‑mTOR↓, 1,  

Migration ⓘ

AP-1↓, 1,   MMP9↓, 1,   TGF-β↓, 4,   TIMP1↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature ⓘ

LOX1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 1,   COX2↓, 2,   IL10↑, 2,   IL1β↓, 1,   IL2↑, 1,   IL4↑, 2,   IL8↓, 2,   Inflam↓, 3,   NF-kB↓, 1,   TLR4↓, 1,   TNF-α↓, 3,  

Drug Metabolism & Resistance ⓘ

BioAv↝, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,  
Total Targets: 38

Scientific Paper Hit Count for: TGF-β, transforming growth factor-beta
2 Radiotherapy/Radiation
1 Alpha-Lipoic-Acid
1 Artemisinin
1 Berberine
1 Caffeine
1 Garcinol
1 Cisplatin
1 Paclitaxel
1 Gossypol
1 Naringin
1 Propolis -bee glue
1 Selenium
1 Silymarin (Milk Thistle) silibinin
1 Thymoquinone
1 doxorubicin
1 Ursolic acid
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:0  Cells:%  prod#:%  Target#:304  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page